Triple negative breast cancer (TNBC) has recently been recognized as an important subgroup of breast cancer with a distinct outcome and therapeutic approach when compared to other subgroups of breast cancer. TNBC is primarily, but not exclusively, comprised of a molecularly distinct subtype of breast cancer, the basal-like subtype. We
Introduction
Triple-negative breast cancer (TNBC; ER, PR, and HER2-negative breast cancer) remains a major challenge to physicians and patients, and a source of great interest to laboratory investigators. Although TNBC accounts for a relatively small minority of breast cancer cases, it is responsible for a disproportionate number of breast cancer deaths. Moreover, there have been fewer advances in the treatment of TNBC than has been seen with other subtypes. For these reasons, new research initiatives for TNBC are critical. The investigation of TNBC is one facet of an emerging effort that regards breast cancer as a collection of separate diseases rather than a single heterogeneous entity, an important step towards the individualization of therapy.
1 Here we attempt to 1). Define TNBC and compare and contrast it with basal-like disease (a term frequently used interchangeably with triple negative disease); 2). Outline established and proposed risk factors; 3). Review the molecular, pathologic, and clinical features of triple negative disease; 4). Provide an overview of ongoing therapeutic trials and; 5). Suggest possible avenues for future research.
Triple negative or basal-like breast cancer: which is it?
TNBC has become a commonly used descriptor for malignancies that are estrogen 5, 6 In addition to variability in expression of known basal markers, there is also heterogeneity within TNBC for other potentially relevant features including p53 mutation, BRCA1 mutation or expression 7 , expression of αB-crystallin 8, 9 and degree of expression of immune response genes 5, 10 ( Figure 2) . Because of this discordance and potential for misclassification, in this review we will refer to basal-like breast cancer (BLBC) when gene expression array or more sophisticated immunophenotypes were used for identification and TNBC when the analysis was limited to clinical assays.
Basal-like breast cancer
Gene expression arrays have reproducibly identified breast cancer molecular subtypes with clinical and prognostic implications. These studies confirmed the importance of hormone receptors and HER2 as central to the biologic variance among breast cancers, and have provided additional data regarding the biology of these subtypes. One of the subtypes is the basal-like. The term "basal-like" breast cancer comes from its expression pattern resemblance to that of the myoepithelial cell of the breast, however this definition does not necessarily imply that basal-like tumors arise from these cells. From a historical perspective, this subgroup had been identified long ago by studies examining phenotype and cytokeratin profiles. 11, 12 Using gene expression profiling or immunohistochemical surrogates, this subgroup of tumors are notable not only for low expression of hormone receptor-and HER2-related genes, but also for high expression of proliferative genes, including Ki-67, and for expression of a characteristic "basal-like" gene cluster, 2, 3, 13 which includes high expression of basal cytokeratins (CK) such as CK5 and 17, caveolin-1, the epidermal growth factor receptor (EGFR), ∝B-crystallin, and c-KIT (Figure 3 ).
Other notable characteristics of this subtype include frequent p53 mutations 2, 13 , gene copy number aberrations and evidence of genomic instability [14] [15] [16] [17] , and Rb pathway inactivation 18, 19 ( Figure 4 ).
There is an intriguing association of BLBC with germline BRCA1 mutations 13, 20 , one of the most important forms of hereditary breast cancer. At least three-quarters of BRCA1-related breast cancers are basal-like by microarray 13 or by immunohistochemistry. 21 Genomic instability appears characteristic of both BRCA1-related breast cancer and BLBC, which may reflect aberrant DNA repair pathways that are common to both subtypes of cancer. 22 24, 25 Methylation of the promoter of BRCA1 has been found (mainly in medullary and metaplastic breast cancers) 7, 26, 27 , but there are conflicting data 7, 28 , especially if the studies are limited to BLBC that do not fall into these two categories. Moreover, decreased expression of BRCA1 in BLBC was seen in one study 7 but not in another. 29 In the latter study, one common factor seen in both BLBC and BRCA1-related breast cancer was a defect in the maintenance of normal chromosome X-inactivation. Thus a complex picture emerges: it seems likely that there is considerable heterogeneity within BLBC, as has been suggested by microarray studies 30 ( Figure 2 ). BRCA1-related breast cancers are also not homogeneous: mice conditionally mutant for Brca1 developed at least three different molecular and histological sub-types of breast cancer. 31 This is mirrored in humans as not all breast cancers arising in BRCA1 mutation carriers are TNBC or BLBC.
Interestingly, the proportion of ER-negative tumors in women with BRCA1 mutations decreases with age. Approximately 20% of those younger than 45 years of age at diagnosis have ER-positive disease compared with ~40% for those 55-65 years of age.
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The clinical outcomes for women with sporadic, BLBC compared with those with BRCA1-related cancers are broadly similar, and notable for early (within 5 years)
relapse. In addition to the timing of relapse, the pattern of metastatic spread is also similar for BRCA1-related 33 and BLBC. 34 The characteristics of hereditary BRCA1-associated breast cancer found in sporadic cancers has been termed "BRCA-ness", with potential clinical implications as described further below.
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Risk factors for basal-like breast cancer
BRCA1 mutation confers an exceptionally high risk of developing BLBC, however there may be many other lower penetrance genes that raise this risk either alone or in concert with other genes or with environmental exposures. Identifying these genes will require large scale genetic association studies such as genome wide association studies (GWAS), which are in development.
Although not yet specifically designed to study by subtype, a recent GWAS study uncovered several powerful susceptibility loci for unselected breast cancer. 35 These included five novel susceptibility loci that had never previously been reported in association studies. These included SNPs in: FGR2, chromosome 8q, CASP8, TNRC9, MAP3K1, and LSP1. 35 Very weak associations confined to ER+ breast cancers were also identified with SNPs from 16q12 and 2q35. 36 To date, the majority of these associations appear to be more significantly correlated with ER+ tumors. 37, 38 use of these powerful genetic platforms applied to more selected populations, will help to understand the biology of BLBC and hopefully provide insight to preventive approaches. 54 , and another neoadjuvant trial of women with BRCA1 mutations and TNBC, in which 9 of 10 had pCR to single agent cisplatin. 55 In two platinum-based regimens in the pretreated metastatic setting, response rates of 17% to carboplatin plus cetuximab 56 and 30% to carboplatin plus irinotecan 57 were seen.
These results further support research into the utility of platinating agents in TNBC, however clearly there is a need for additional studies before cisplatin or any similar agent can be considered standard for front-line therapy. The additional benefit of carboplatin added to paclitaxel in triple negative disease will be directly studied in the neoadjuvant trial CALGB 40603. There is little question, however, that better therapies are needed.
Given the lack of targeted therapy for TNBC, strategies that maximize the benefits associated with standard cytotoxic therapy could lead to further reductions in breast cancer recurrence and mortality in women with triple negative disease.
The promise of a targeted approach in this subtype of breast cancer is real, particularly with anti-angiogenic strategies. ECOG 2100, a phase III North American Breast Cancer Intergroup trial, randomized over 700 women who had never received chemotherapy in the metastatic setting to paclitaxel with or without bevacizumab. 58 There was a significant improvement in the primary endpoint of progression free survival with the addition of bevacizumab overall, including the subgroup of patients with largely triple negative disease. In this context, it is notable that BRCA1-related breast cancers are associated with the presence of glomeruloid microvascular proliferation, a marker of increased neo-angiogenesis in cancer. 59 Another recently reported study of the multikinase vascular endothelial growth factor receptor (VEGFR) inhibitor, sunitinib, suggested a response rate of approximately 15% in the pretreated triple negative subset of patients. 60 This approach will be tested directly in the neoadjuvant setting in CALGB 40603, which includes a second randomization to receive or not receive preoperative bevacizumab in addition to the assigned chemotherapy.
Based upon EGFR expression in gene profiling studies and EGFR dependence for growth and proliferation in BLBC cell lines 61 , several groups have examined EGFR targeting in TNBC. Two studies completed to date shed light on this approach. TBCRC 001 was a randomized phase II trial evaluating the role of EGFR inhibition for triple negative metastatic breast cancer. In this study, eligible women received the anti-EGFR monoclonal antibody cetuximab combined with carboplatin, or cetuximab alone with a planned crossover to carboplatin at progression. Not surprisingly, cetuximab alone demonstrated a low response rate and was closed early by design, however response to the combination of cetuximab plus carboplatin was 17% with clinical benefit seen in 29%
of a pretreated population. 56 A similar study examining irinotecan plus carboplatin with or without cetuximab suggested a modestly higher response rate (from 30% to 49%) with the combination in TNBCs on subset analysis.
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The current plan of attack
The optimal therapeutic approach for TNBC will likely include a mixture of targeting the host via an intimate understanding of pharmacogenetics 62 On December 11, 2007 There are additional molecular features that characterize some but not all TN tumors including but not limited to p53 mutation (shown in light blue), BRCA1 germline mutation (shown in dark blue), and alpha B crystallin expression (shown in light green). Which of these various subsets of TN cancer will have clinical differences or treatment implications is yet to be determined. 
